Found: 52
Select item for more details and to access through your institution.
Increased toxicity and reduced clearance of lidocaine by cimetidine.
- Published in:
- 1982
- By:
- Publication type:
- journal article
Pharmacogenetics of Long-Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study.
- Published in:
- Journal of Infectious Diseases, 2005, v. 192, n. 11, p. 1931, doi. 10.1086/497610
- By:
- Publication type:
- Article
Normal Disposition of Oxazepam in Acute Viral Hepatitis and Cirrhosis.
- Published in:
- Annals of Internal Medicine, 1976, v. 84, n. 4, p. 420, doi. 10.7326/0003-4819-84-4-420
- By:
- Publication type:
- Article
Sedative Plasma Concentrations and Delirium Risk in Critical Illness.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Associations between CYP2B6 Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans.
- Published in:
- Journal of Infectious Diseases, 2009, v. 199, n. 6, p. 872, doi. 10.1086/597125
- By:
- Publication type:
- Article
The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2006, v. 80, n. 3, p. 228, doi. 10.1016/j.clpt.2006.06.002
- By:
- Publication type:
- Article
In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2004, v. 76, n. 4, p. 341, doi. 10.1016/j.clpt.2004.07.003
- By:
- Publication type:
- Article
Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: Some answers but still questions<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2004, v. 76, n. 2, p. 99, doi. 10.1016/j.clpt.2004.04.005
- By:
- Publication type:
- Article
CYP2C9 and Oral Anticoagulation Therapy with Acenocoumarol and Warfarin: Similarities yet Differences<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2004, v. 75, n. 5, p. 376, doi. 10.1016/j.clpt.2004.01.007
- By:
- Publication type:
- Article
Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2003, v. 73, n. 3, p. 253, doi. 10.1067/mcp.2003.26a
- By:
- Publication type:
- Article
Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2003, v. 73, n. 1, p. 41, doi. 10.1067/mcp.2003.10
- By:
- Publication type:
- Article
Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2002, v. 72, n. 3, p. 288, doi. 10.1067/mcp.2002.127398
- By:
- Publication type:
- Article
Identification of functionally variant MDR1 alleles among European Americans and African Americans<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2001, v. 70, n. 2, p. 189, doi. 10.1067/mcp.2001.117412
- By:
- Publication type:
- Article
CYP3A activity in European American and Japanese men using midazolam as an in vivo probe<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2001, v. 69, n. 5, p. 333, doi. 10.1067/mcp.2001.115447
- By:
- Publication type:
- Article
CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4<sup>*</sup>1B 5′-promoter region polymorphism<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2000, v. 68, n. 1, p. 82, doi. 10.1067/mcp.2000.108506
- By:
- Publication type:
- Article
Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: A cocktail study with dextromethorphan and chloroguanide alone and in combination<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1999, v. 66, n. 6, p. 582, doi. 10.1053/cp.1999.v66.103401001
- By:
- Publication type:
- Article
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1999, v. 66, n. 3, p. 224, doi. 10.1016/S0009-9236(99)70029-9
- By:
- Publication type:
- Article
Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1998, v. 64, n. 1, p. 8, doi. 10.1016/S0009-9236(98)90017-0
- By:
- Publication type:
- Article
Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1997, v. 62, n. 5, p. 527, doi. 10.1016/S0009-9236(97)90048-5
- By:
- Publication type:
- Article
Dietary salt increases first-pass elimination of oral quinidine<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1997, v. 61, n. 3, p. 292, doi. 10.1016/S0009-9236(97)90161-2
- By:
- Publication type:
- Article
Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1996, v. 60, n. 4, p. 396, doi. 10.1016/S0009-9236(96)90196-4
- By:
- Publication type:
- Article
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1996, v. 59, n. 5, p. 491, doi. 10.1016/S0009-9236(96)90177-0
- By:
- Publication type:
- Article
Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1996, v. 59, n. 1, p. 47, doi. 10.1016/S0009-9236(96)90023-5
- By:
- Publication type:
- Article
Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1995, v. 57, n. 6, p. 645, doi. 10.1016/0009-9236(95)90227-9
- By:
- Publication type:
- Article
Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity.
- Published in:
- Clinical Pharmacology & Therapeutics, 1994, v. 56, n. 4, p. 359, doi. 10.1038/clpt.1994.150
- By:
- Publication type:
- Article
Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population.
- Published in:
- Clinical Pharmacology & Therapeutics, 1994, v. 55, n. 5, p. 492, doi. 10.1038/clpt.1994.62
- By:
- Publication type:
- Article
Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men.
- Published in:
- Clinical Pharmacology & Therapeutics, 1993, v. 54, n. 6, p. 621, doi. 10.1038/clpt.1993.199
- By:
- Publication type:
- Article
Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: A case report.
- Published in:
- Clinical Pharmacology & Therapeutics, 1993, v. 53, n. 1, p. 89, doi. 10.1038/clpt.1993.13
- By:
- Publication type:
- Article
The disposition of dapsone in cirrhosis.
- Published in:
- Clinical Pharmacology & Therapeutics, 1992, v. 51, n. 6, p. 689, doi. 10.1038/clpt.1992.81
- By:
- Publication type:
- Article
Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans.
- Published in:
- Clinical Pharmacology & Therapeutics, 1991, v. 50, n. 5, p. 520, doi. 10.1038/clpt.1991.177
- By:
- Publication type:
- Article
The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects.
- Published in:
- Clinical Pharmacology & Therapeutics, 1990, v. 48, n. 6, p. 619, doi. 10.1038/clpt.1990.204
- By:
- Publication type:
- Article
Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquin, and mephenytoin.
- Published in:
- Clinical Pharmacology & Therapeutics, 1990, v. 48, n. 3, p. 286, doi. 10.1038/clpt.1990.151
- By:
- Publication type:
- Article
Differences in plasma binding of drugs between Caucasians and Chinese subjects.
- Published in:
- Clinical Pharmacology & Therapeutics, 1990, v. 48, n. 1, p. 10, doi. 10.1038/clpt.1990.111
- By:
- Publication type:
- Article
Influence of debrisoquin phenotype on the inducibility of propranolol metabolism.
- Published in:
- Clinical Pharmacology & Therapeutics, 1989, v. 45, n. 4, p. 439, doi. 10.1038/clpt.1989.52
- By:
- Publication type:
- Article
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
- Published in:
- Clinical Pharmacology & Therapeutics, 1989, v. 45, n. 1, p. 72, doi. 10.1038/clpt.1989.11
- By:
- Publication type:
- Article
In vivo inhibition of human CYP1A2 activity by oltipraz.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Modulation of CYP2EI activity by isoniazid in rapid and slow N-acetylators.
- Published in:
- British Journal of Clinical Pharmacology, 1997, v. 43, n. 1, p. 99, doi. 10.1111/j.1365-2125.1997.tb00144.x
- By:
- Publication type:
- Article
Disposition of diazepam in young and elderly subjects after acute and chronic dosing.
- Published in:
- British Journal of Clinical Pharmacology, 1996, v. 42, n. 2, p. 147, doi. 10.1046/j.1365-2125.1996.03642.x
- By:
- Publication type:
- Article
Single Plasma Concentrations of 1'-Hydroxymidazolam or the Ratio of 1'-Hydroxymidazolam:Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2002, v. 42, n. 10, p. 1079, doi. 10.1177/009127002237986
- By:
- Publication type:
- Article
Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques.
- Published in:
- Journal of Clinical Pharmacology, 2002, v. 42, n. 4, p. 376, doi. 10.1177/0091270002424002
- By:
- Publication type:
- Article
Pyridoxal 5′-Phosphate (PLP).
- Published in:
- Nutrition Reviews, 1977, v. 35, n. 11, p. 315, doi. 10.1111/j.1753-4887.1977.tb06509.x
- By:
- Publication type:
- Article
Reduction of liver plasma flow by caffeine and theophylline.
- Published in:
- Clinical Pharmacology & Therapeutics, 1986, v. 40, n. 5, p. 506, doi. 10.1038/clpt.1986.215
- By:
- Publication type:
- Article
Encainide disposition in patients with chronic cirrhosis.
- Published in:
- Clinical Pharmacology & Therapeutics, 1986, v. 40, n. 2, p. 148, doi. 10.1038/clpt.1986.155
- By:
- Publication type:
- Article
Furosemide kinetics and dynamics in patients with cirrhosis.
- Published in:
- Clinical Pharmacology & Therapeutics, 1986, v. 40, n. 1, p. 14, doi. 10.1038/clpt.1986.132
- By:
- Publication type:
- Article
Encainide disposition in patients with renal failure.
- Published in:
- Clinical Pharmacology & Therapeutics, 1986, v. 40, n. 1, p. 64, doi. 10.1038/clpt.1986.140
- By:
- Publication type:
- Article
Co-inheritance of the polymorphic metabolism of encainide and debrisoquin.
- Published in:
- Clinical Pharmacology & Therapeutics, 1986, v. 39, n. 3, p. 282, doi. 10.1038/clpt.1986.40
- By:
- Publication type:
- Article
Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing.
- Published in:
- Clinical Pharmacology & Therapeutics, 1983, v. 33, n. 5, p. 603, doi. 10.1038/clpt.1983.81
- By:
- Publication type:
- Article
Furosemide disposition in cirrhosis.
- Published in:
- Clinical Pharmacology & Therapeutics, 1982, v. 31, n. 6, p. 719, doi. 10.1038/clpt.1982.101
- By:
- Publication type:
- Article
Meperidine disposition in man: Influence of urinary pH and route of administration.
- Published in:
- Clinical Pharmacology & Therapeutics, 1981, v. 30, n. 5, p. 619, doi. 10.1038/clpt.1981.213
- By:
- Publication type:
- Article
Deuterium labelling of the antidepressant drug doxepin for disposition studies in human subjects.
- Published in:
- Journal of Labelled Compounds & Radiopharmaceuticals, 1990, v. 28, n. 9, p. 1037, doi. 10.1002/jlcr.2580280908
- By:
- Publication type:
- Article